Single domain camel antibodies: Current status

Reviews in Molecular Biotechnology

Volumn 74, Issue 4, 2001, Pages 277-302

  Muyldermans, Serge ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Camels; Heavy chain variable domain of conventional antibodies, VH; Heavy chain antibodies; Llama; Molecular recognition units; Single domain antibody

Indexed keywords

ARTIODACTYLA; CAMELIDAE; CAMELUS DROMEDARIUS; LAMA (CAMEL); LAMA GLAMA;

IMMUNOGLOBULIN HEAVY CHAIN; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ANIMAL; BIOTECHNOLOGY; CAMEL; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; MOLECULAR CLONING; MOLECULAR GENETICS; MOUSE; PROTEIN ENGINEERING; PROTEIN TERTIARY STRUCTURE; REVIEW; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANIMALS; BIOTECHNOLOGY; CAMELS; CLONING, MOLECULAR; CRYSTALLOGRAPHY, X-RAY; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS;

EID: 0035715877     PISSN: 13890352     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1389-0352(01)00021-6     Document Type: Article

References (107)

1. Standard conformations for the canonical structures of immunoglobulins
2. 'Phytoantibodies': A general vector for the expression of immunoglobulin domains in transgenic plants
3. Use of antibody fragments in immunoaffinity chromatography
4. Escherichia coli secretion of an active chimeric antibody fragment
5. Single-chain antigen binding protein
6. Cytolysis of leukemic B-cells by T-cells activated via two biospecific antibodies
7. Kinetic analysis of recombinant antibody-antigen interactions: Relation between structural domains and antigen binding
8. Assembly of functional antibodies from immunoglobulin heavy and light chains synthesised in E. coli
9. Production of functional chimaeric mouse/human antibody
10. Strategies for expressing human antibody repertoires in transgenic mice
11. Generation of antibody activity from immunoglobulin polypeptide chains produced in E. coli
12. The selection of intracellular antibodies
13. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs
14. Structural repertoire of human VH segments
15. Canonical structures for the hypervariable regions of immunoglobulins
16. Conformations of immunoglobulin variable regions
17. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms
18. Camelising human antibody fragments: NMR studies on VH domains
19. Antibody VH domains as small recognition units
20. Affinity improvement of single antibody VH domains. Residues in all three hypervariable regions affect antigen binding
21. Single antibody domains as small recognition units: Design and in vitro antigen selection of camelised, human VH domains with improved protein stability
22. Selection of high affinity phage antibodies from phage display libraries
23. A large non-immunised human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies
24. A single-domain antibody fragment in complex with RNase A: Non-canonical loop structures and nanomolar affinity using two CDR loops
25. Canonical antigen-binding loop structures in immunoglobulins: More structures, more canonical classes?
26. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme
27. Recent advances in the large-scale production of antibody fragments using lower eukaryotic micro-organisms
28. Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae
29. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies
30. A comparison of strategies to stabilise immunoglobulin Fv fragments
31. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs
32. Isolation of high affinity human antibodies directly from large synthetic repertoires
33. Naturally occurring antibodies devoid of light chains
34. Human antibodies from transgenic mice
35. Llama heavy-chain V regions consist of at least four district subfamilies revealing novel sequence features
36. Assembly and secretion of heavy chains that do not associate post-translationally with immunoglobulin heavy chain-binding protein
37. Diabodies: Small bivalent and bispecific antibody fragments
38. Multi-subunit proteins on the surface of filamentous phage: Methodologies for displaying antibody (Fab) heavy and light chains
39. Antibody phage display technology and its applications
40. Recombinant antibody fragments
41. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda
42. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in E. coli
43. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomised with trinucleotides
44. Continuous cultures of fused cells secreting antibody of predefined specificity
45. Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria
46. Will immunogenicity limit the use, efficacy and future development of therapeutic monoclonal antibodies?
47. Protein clefts in molecular recognition and function
48. Therapeutic peptides revisited
49. Systematic exploration of the antigen binding activity of synthetic peptides isolated from the variable regions of immunoglobulins
50. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies
51. Elbow motion in immunoglobulins involves a molecular ball-and-socket joint
52. Comparative properties of the single chain antibody and Fv derivatives of mAb 4-4-20: Relationship between interdomain interactions and high affinity for fluourescein ligand
53. Bypassing immunisation. Human antibodies from V gene libraries displayed on phage
54. Affinity selection of a camelised VH domain antibody inhibitor of hepatitis C virus NS3 protease
55. Both DNA strands of antibody genes are hypermutation targets
56. Conformations of the third hypervariable region in the VH domain of immunoglobulins
57. Immune response of the llama (Lama glama) to tetanus toxoid vaccination
58. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains
59. Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies
60. Loss of splice consensus signal is responsible for the removal of the entire CH1 domain of the functional camel IgG2A heavy chain antibodies
61. Camel heavy-chain antibodies: Diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire
62. The specific variable domain of camel heavy-chain antibodies is encoded in the germline
63. Disruption of the hydrophobic patches at the antibody variable/constant domain interface: Improved in vivo folding and physical characterisation of an engineered scFv fragment
64. Antibody fragments from 'single pot' phage display library as immunochemical reagents
65. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties
66. Anatomy of the antibody molecule
67. X-Ray crystallography of antibodies
68. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel
69. The power of clonal selection
70. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: Disulfide stabilised Fv immunotoxins
71. An antibody single-domain phage display library of a native heavy chain variable region: Isolation of functional single-domain VH molecules with a unique interface
72. Somatic hyperconversion diversifies the single VH gene of the chicken with a high incidence in the D region
73. Multivalent antibody fragments with high functional affinity for a tumour-associated carbohydrate antigen
74. Rearrangement of the former VL interface in the solution structure of a camelised, single domain VH antibody
75. Reshaping human antibodies for therapy
76. Single domain antibodies: Comparison of camel VH and camelised human VH domains
77. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases
78. Human IgA and IgG F(AB′)2 that bind to staphylococcal protein A belong to the VH III subgroup
79. Heavy chain diseases: Current findings and concepts
80. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate
81. Redefining the minimal antigen-binding fragment
82. Structural classification of CDR-H3 in antibodies
83. H3-rules: Identification of CDR3-H3 structures in antibodies
84. Bacterial expression of immunoglobulin fragments
85. Assembly of functional immunoglobulin Fv fragment in Escherichia coli
86. The crystal structure of a llama heavy chain variable domain
87. Camelid heavy-chain variable domains provide efficient combining sites to haptens
88. Transgenic plants expressing a functional single-chain Fv antibody are specifically protected from virus attack
89. 'Peptabody': A new type of high avidity binding protein
90. Somatic generation of antibody diversity
91. Camel single domain antibody inhibits enzyme by mimicking carbohydrate substrate
92. Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama
93. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies
94. Human antibodies with sub-nanomolar affinities isolated from a large non-immunised phage display library
95. Selection of antibodies for intracellular function using a two-hybrid in vivo system
96. Comparison of llama VH sequences from conventional and heavy chain antibodies
97. Binding activities of a repertoire of single immunoglobulin variable domains secreted from E. coli
98. Antibody-antigen interactions
99. An improved linker for scFv with reduced aggregation and enhanced proteolytic stability
100. Somatic hypermutation introduces insertions and deletions into immunoglobulin V genes
101. Making antibodies by phage display technology
102. Man-made antibodies
103. The structure of the llama heavy chain constant genes reveals a mechanism for heavy-chain antibody formation
104. Tumor localisation of anti-CEA single chain Fvs: Improved targeting by non-covalent dimers
105. Length distribution of CDR H3 in antibodies
106. Rapid tumour penetration of a single-chain Fv and comparison with other immunoglobulin forms